Zymeworks (ZYME) EVP buys 459 shares under ESPP plan on Jan 6 2026

Rhea-AI Filing Summary

Zymeworks Inc. executive Patterson Leone, EVP and Chief Business & Financial Officer, reported buying common stock through the company’s employee stock purchase plan. On January 6, 2026, Leone acquired 459 shares of common stock at a price of $10.55 per share, bringing reported beneficial ownership to 459 shares held directly. The filing notes these shares were purchased under Zymeworks’ Amended and Restated Employee Stock Purchase Plan for the purchase period from July 1, 2025 through December 31, 2025, at a price equal to 85% of the closing price of the stock on July 1, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

PATTERSON LEONE D

(Last) (First) (Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN DE 19709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Bus & Fin Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		A(1)		459	A	$10.55	459	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares of common stock purchased pursuant to the Issuer's Amended and Restated Employee Stock Purchase Plan (ESPP) for the ESPP purchase period July 1, 2025 through December 31, 2025. In accordance with the ESPP, the shares of common stock were purchased at a price equal to 85% of the closing price of the Issuer's common stock on July 1, 2025.

	/s/ Daniel Dex, Attorney-in-Fact	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZYME report in this Form 4?

The Form 4 reports that executive Patterson Leone acquired 459 shares of Zymeworks Inc. common stock on January 6, 2026.

Who is the reporting person in the ZYME Form 4 filing?

The reporting person is Patterson Leone, who serves as Zymeworks Inc.’s EVP, Chief Business & Financial Officer.

At what price were the ZYME shares acquired in this transaction?

The 459 shares of Zymeworks common stock were acquired at a price of $10.55 per share.

How many ZYME shares does the insider own after this transaction?

Following this transaction, Patterson Leone is reported as beneficially owning 459 shares of Zymeworks common stock, held directly.

Was the ZYME insider purchase made under an employee stock purchase plan?

Yes. The shares were acquired under Zymeworks’ Amended and Restated Employee Stock Purchase Plan (ESPP) for the period from July 1, 2025 through December 31, 2025.

What discount did the ZYME ESPP provide for this share purchase?

The filing states the ESPP purchase price equaled 85% of the closing price of Zymeworks common stock on July 1, 2025.